- GeneTether Therapeutics (GTTX) has been granted a patent from the United States Patent and Trademark Office
- The patent, entitled “Modified Nucleic Acid Editing Systems for Tethering Donor DNA” is related to its GeneTether platform technology
- CEO Roland Boivin sat down with Coreena Robertson to discuss the news
- GeneTether Therapeutics is an innovative genetic medicines company
- Shares of GeneTether Therapeutics Inc. (GTTX) opened trading at C$0.35
GeneTether Therapeutics (GTTX) has been granted a patent from the United States Patent and Trademark Office.
Patent #11,339,385 entitled “Modified Nucleic Acid Editing Systems for Tethering Donor DNA” is related to its GeneTether platform technology.
GeneTether CEO Roland Boivin sat down with Coreena Robertson to discuss the news.
“We are very excited about the grant of this composition of matter patent, which significantly strengthens our wholly-owned intellectual property portfolio. We believe that our technology, which showed a 7x higher gene editing efficiency in our proof-of-concept study, applies to most gene correction/gene complementation strategies, regardless of organ or disease. Further, the broad claims are not limited to any particular nuclease. They provide protection for the GeneTether platform technology as it relates to Cas nucleases such as cas9and other nucleases, including TALENs, meganucleases, and zinc fingers. This reinforces the commercial potential for GeneTether, both internally and with potential external collaborators. There are 625 known monogenic disorders associated with kidney and urological traits. We believe our technology may allow us to develop treatments for common subtypes of both autosomal dominant tubulo-interstitial kidney disease (ADTKD) and autosomal dominant polycystic kidney disease (ADPKD).”
GeneTether is focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome for gene correction. The company is leveraging its platform technology to develop curative therapies to treat rare genetic diseases.
Shares of GeneTether Therapeutics Inc. (GTTX) opened trading at C$0.35